Severe renal arteriosclerosis in diagnostic lupus nephritis biopsies is associated with 9-fold higher odds of atherosclerotic cardiovascular disease.
A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.
In a randomized trial, belimumab (Benlysta) vs placebo added to standard therapy demonstrated superiority in achieving the primary efficacy renal response at 104 weeks.
Researchers evaluated the efficacy and safety of the induction treatment with mycophenolate mofetil and cyclophosphamide for lupus nephritis.
Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.
The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.
Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis.
Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.